HIV Infection Of The Central Nervous System (R01) | Apply Online

Opportunity Summary:

The HIV Infection Of The Central Nervous System (R01) opportunity (Funding Opportunity Number PA-07-089) is a National Institutes of Health (NIH) funding announcement designed to support research that explains how HIV-1 causes problems in the brain and nervous system. The main focus is on uncovering the pathogenic mechanisms behind HIV-associated neurobehavioral and neurological dysfunction, meaning it is looking for studies that clarify why and how HIV infection can lead to cognitive, behavioral, and neurological changes. The program is explicitly interested in work conducted in both domestic and international settings, reflecting the global nature of HIV and the need to understand CNS complications across diverse populations, viral subtypes, co-infections, and health care environments.

The larger goal of the announcement is practical and translational: to build the scientific foundation needed for faster development of interventions that can prevent or treat the effects of HIV-1 on the central nervous system (CNS). In other words, NIH is not only looking for descriptive studies that document CNS outcomes, but also research that helps move the field toward actionable strategies, such as improved therapeutic approaches, better prevention of neurological injury, and more effective management of HIV-related CNS disease. Because HIV can affect the CNS through multiple routes (including viral persistence in sanctuary sites, immune activation and inflammation, neurotoxicity, vascular effects, and interactions with substances or co-morbid conditions), the announcement leaves room for a wide range of mechanistic angles.

The scope is intentionally broad and spans the full pipeline from basic science through clinical application. Applications may include fundamental laboratory research (for example, studies of viral entry into CNS compartments, neuroinflammatory signaling pathways, host genetic susceptibility, or cellular targets such as microglia and macrophages), as well as more clinically oriented research dealing with diagnosis and treatment (for example, biomarkers of CNS involvement, neuroimaging approaches, clinical assessments of neurocognitive impairment, or trials and strategies aimed at preventing or reducing neurological damage). This breadth signals that NIH is seeking both discovery-driven science and patient-centered work, as long as it advances understanding of HIV’s impact on the CNS and contributes to the long-term aim of better interventions.

The primary mechanism of support for this opportunity is the NIH Research Project Grant (R01), which is generally suited for well-developed projects with clear aims and a substantial research plan. The announcement also notes that projects with related or identical scientific scope may be submitted under other NIH mechanisms, specifically the Small Research Grant (R03) and the Exploratory/Developmental Grant (R21), through separate but linked announcements (PA-06-180 and PA-06-181). In practical terms, this means investigators can choose a mechanism that fits the maturity and scale of their project, whether that is a smaller, more limited study (R03), a higher-risk early-stage concept (R21), or a more comprehensive research program (R01).

Collaboration is encouraged but not mandatory. NIH signals interest in multidisciplinary research teams and collaborative alliances, which fits the complexity of HIV-associated CNS disease, where progress often requires blending expertise in virology, immunology, neuroscience, neurology, psychiatry, neuropsychology, pharmacology, epidemiology, and clinical trial methods. At the same time, the announcement does not require formal consortia or multi-site structures, leaving room for strong single-investigator or single-institution proposals if they address the scientific goals effectively.

From an administrative and eligibility standpoint, this is a discretionary grant opportunity with no cost sharing or matching requirement. It is open to a wide range of applicant types, including public and private institutions of higher education, nonprofits (including 501(c)(3) and other nonprofit structures), state, county, city, township, and special district governments, independent school districts, tribal governments and tribal organizations, public housing authorities/Indian housing authorities, and for-profit entities (including small businesses and other for-profits). Importantly, foreign institutions are eligible to apply, and eligible federal agencies may also apply. Faith-based and community-based organizations are also permitted, which can matter for projects involving community engagement, clinical recruitment, or implementation-oriented research approaches related to HIV and neurological outcomes.

Key timing information indicates that the opportunity used multiple receipt dates rather than a single deadline, meaning applications were accepted on recurring NIH submission cycles during the active period of the announcement. The posting date is listed as November 22, 2006, with a creation date of December 5, 2008, and an archive date of October 2, 2010. The CFDA program areas associated with the announcement include mental health research, alcohol research, drug abuse and addiction research, and broader neuroscience and neurological disorders extramural research programs (CFDA numbers 93.242, 93.273, 93.279, and 93.853), which reflects the overlap between HIV-associated CNS issues, neuropsychiatric outcomes, substance use comorbidities, and neurological disease mechanisms.

Overall, PA-07-089 is best understood as an NIH R01 funding pathway aimed at accelerating progress on HIV-related CNS complications by supporting research that explains mechanisms of disease and helps enable the development of effective clinical interventions, ranging from improved diagnostics to better therapeutic and preventive strategies. The full announcement was hosted on the NIH grants site at http://grants.nih.gov/grants/guide/pa-files/PA-07-089.html, with NIH Office of Extramural Research (OER) webmaster contact information provided for access and technical linking issues.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: HIV/AIDS, Severe Mental Illness And Homelessness (R01)

Previous opportunity: Indo U.S. Vaccine Action Program (VAP) Small Research Grant Program (R03)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 07 089

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 07 089) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 07 089", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.